The FDA-cleared PrecivityAD2® test is now available to order

Patient Resources

FAQ

How do biomarkers help in diagnosis and treating Alzheimer’s disease?

Dr. Randall Bateman, MD, Scientific Co-Founder, C2N Diagnostics

Currently the biomarkers can be used to diagnose people to see if they have amyloid plaques and if they do have amyloid plaques that's consistent with Alzheimer's disease. What that means for those patients is that if they meet other criteria they potentially could be treated.  We could treat them to remove those amyloid plaques so that's currently happening. For the future, what's coming is the potential for prevention. If we could figure out when to treat people and how to treat people in a way to delay the onset of the symptoms, we might be able to give people years of dementia free life. These same biomarkers we can use to predict who is likely to get Alzheimer's disease based on the presence of those amyloid plaques as well as using other biomarkers to potentially predict when they might get it and to think about treatment paradigms of who to treat and what to treat them with.

What sets LC-MS apart from traditional immunoassays in Alzheimer’s disease diagnosis?

Kris Kirmess, PhD, Senior Director, Clinical Chemistry and Commercial Assays, C2N Diagnostics

LC-MS or liquid chromatography mass spectrometry is a very specific technique where we're able to identify proteins or peptides on their mass with the charge level so we could essentially fingerprint signatures from biomarkers and have the exact identity of them compared to immunoassays which lack in specificity and lack the tools needed to properly identify whether or not that is the true biomarker or not.  We do targeted LC-MS and so essentially what that means is we know the target up front and we're able to set the mass spectrometer to hone in on the peptide or fragment of interest and parse it out from everything else in the mixture from that plasma sample and so this is where mass spectrometry allows us to be extremely specific with the identity of the biomarker of interest over immunoassays.

What are the likely advancements in brain health testing?

David Holtzman, MD, Scientific Co-Founder, C2N Diagnostics

What is very exciting is that what will probably happen is when people get to a certain age, say 40, they will get a blood test that will look to see whether they're developing the early changes of Alzheimer's disease or not. If it's negative then they'll probably get screened again 10 years later or 10 years later.  If it's positive, hopefully intervention can begin occurring at that point so that the disease as we know it can be prevented.

What’s C2N’s role in Alzheimer’s disease staging innovation?

Joel Braunstein, MD, CEO, C2N Diagnostics

For C2N we think a lot about disease staging. It allows us to start thinking about prevention strategies because to properly intervene on prevention you need to understand the stage at which the patient exists. We are seeing that the Alzheimer’s Association has recently introduced diagnostic criteria that puts the first symptom onset of Alzheimer’s disease at stage four disease. That means there is stages one – three that don’t involve any symptoms whatsoever. So, the ability to properly stage a disease is going to be heavily predicated on highly accurate blood tests.

How does C2N improve early Alzheimer’s disease detection?

Joel Braunstein, MD CEO, C2N Diagnostics

There's three modalities for getting a precise diagnosis of Alzheimer's disease or ruling out the disease and that includes cerebral spinal fluid analysis through lumbar puncture, amyloid PET scans, or highly accurate blood test like the PrecivtyAD2® test. Because of the burden, invasiveness, cost, logistic challenges, and inaccessibility of cerebral spinal fluid analysis and amyloid PET, blood tests really represent a highly attractive option and really the preferred option for many patients and providers when they learn about the quality and accuracy of these tests.

What makes blood biomarkers vital for Alzheimer’s disease prevention trials?

Dr. B. Joy Snider, Professor, Neurology, Washington University School of Medicine

Blood biomarkers have had a huge impact on AD clinical research because they enable us to screen a large number of people and figure out who is likely to have the underlying Alzheimer disease pathology. They offer a much less expensive, much less invasive way to do screenings particularly in studies of people before they have symptoms. For prevention studies that's huge as it reduces the cost of the study by half or more, it reduces the time it takes to recruit, it reduces the burden on the patients, and it enables us to reach more diverse populations as many folks can't get a PET scan or don't want to have a spinal fluid test. It’s really made a huge change in clinical research.

Resources on Alzheimer’s Disease

March 05, 2026

National Institute on Aging (NIA): Offers comprehensive information on Alzheimer’s disease, including a video on “How Alzheimer’s Changes the Brain.”

March 05, 2026

NIA Alzheimer’s Disease Education and Referral (ADEAR) Center: 800-438-4380 (toll-free) - 8:30 a.m. to 5:00 p.m. Eastern Time, Monday – Friday. NIA’s ADEAR Center offers information, Spanish language resources, clinical trial information and free print publications about Alzheimer’s disease and related dementias for families, caregivers, and health professionals.

March 05, 2026

Center for Disease Control (CDC) and Prevention – Alzheimer’s disease: Offers comprehensive information on Alzheimer’s disease. Including additional links to assist in the understanding of the disease.

March 05, 2026

U.S. Department of Veterans Affairs: Dementia Care (including Alzheimer’s) & VA Research on Alzheimer’s Disease

March 05, 2026

Alzheimer's Association: 800-272-3900 (toll-free) 24/7 support line - Available in all languages. 866-403-3073 (TTY/toll-free). Visit the Alzheimer’s Association Web site for a variety of helpful resources including: Inside the Brain video of how the mind works, 10 early signs and symptoms of Alzheimer’s and communicating with doctors or healthcare professionals.

March 05, 2026

MedlinePlus: National Library of Medicine offers resources and information about Alzheimer’s disease.

March 05, 2026

BrightFocus Foundation: Explore the Alzheimer’s Tool Kit on understanding Alzheimer’s, managing Alzheimer’s and living with the disease.

March 05, 2026

Alzheimer’s Drug Discovery Foundation (ADDF): ADDF is a non-profit foundation committed to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s disease. Cognitive Vitality offers a seven-step brain health program.

March 05, 2026

UsAgainstAlzheimer’s (UsA2): UsA2 is an organization committed to ending Alzheimer’s through effective leadership, collaborative advocacy and strategic investments.

The information presented on or through this document and any accompanying communications are made available solely for general information purposes. This information is not intended to provide medical advice or health care advice nor is it intended to be relied on for medical diagnosis or treatment. Always seek the advice of a physician or other qualified health care provider concerning questions or concerns that you have regarding a medical condition, treatment or test. Do not disregard any medical advice or postpone obtaining medical advice due to any information you have read on this document and any accompanying communications. For the full Disclaimer Statement, see our Terms of Use.